Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Research & Development (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Research & Development for 9 consecutive years, with $9.6 million as the latest value for Q4 2025.

  • Quarterly Research & Development changed N/A to $9.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $40.6 million for FY2025, 48.29% down from the prior year.
  • Research & Development for Q4 2025 was $9.6 million at Soleno Therapeutics, up from $8.4 million in the prior quarter.
  • The five-year high for Research & Development was $13.5 million in Q1 2025, with the low at $8.4 million in Q3 2025.